Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Summit Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 57 | 86 | +29 |
| Shares | 8.10M | 21.0M | +12.9M (+159.8%) |
| Value | $34.5M | $37.0M | +$2.44M (+7.1%) |
New holders (35)
Institutions that held Summit Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (6)
Institutions that held Summit Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| DekaBank Deutsche Girozentrale | 100,000 | $531.0K |
| Bridgeway Capital Management, LLC | 89,100 | $378.7K |
| Kapitalo Investimentos Ltda | 57,200 | $243.1K |
| 683 Capital Management, LLC | 50,838 | $216.1K |
| Renaissance Technologies LLC | 23,300 | $99.0K |
| Gsa Capital Partners LLP | 12,500 | $53.0K |